Background: Extracorporeal membrane oxygenation (ECMO) has become an established rescue therapy for severe acute respiratory distress syndrome (ARDS) in several etiologies including influenza A H1N1 pneumonia. The benefit of receiving ECMO in coronavirus disease 2019 (COVID-19) is still uncertain. The aim of this analysis was to compare the outcome of patients who received veno-venous ECMO for COVID-19 and Influenza A H1N1 associated ARDS. Methods: This was a multicenter retrospective cohort study including adults with ARDS, receiving ECMO for COVID- 19 and influenza A H1N1 pneumonia between 2009 and 2021 in seven Italian ICU. The primary outcome was any- cause mortality at 60 days after ECMO initiation. We used a multivariable Cox model to estimate the difference in mor- tality accounting for patients’ characteristics and treatment factors before ECMO was started. Secondary outcomes were mortality at 90 days, ICU and hospital length of stay and ECMO associated complications. Results: Data from 308 patients with COVID-19 (N = 146) and H1N1 (N = 162) associated ARDS who had received ECMO support were included. The estimated cumulative mortality at 60 days after initiating ECMO was higher in COVID-19 (46%) than H1N1 (27%) patients (hazard ratio 1.76, 95% CI 1.17–2.46). When adjusting for confounders, specifically age and hospital length of stay before ECMO support, the hazard ratio decreased to 1.39, 95% CI 0.78–2.47. ICU and hospital length of stay, duration of ECMO and invasive mechanical ventilation and ECMO-associated hemor- rhagic complications were higher in COVID-19 than H1N1 patients. Conclusion: In patients with ARDS who received ECMO, the observed unadjusted 60-day mortality was higher in cases of COVID-19 than H1N1 pneumonia. This difference in mortality was not significant after multivariable adjust- ment; older age and longer hospital length of stay before ECMO emerged as important covariates that could explain the observed difference.
Extracorporeal membrane oxygenation for COVID-19 and influenza H1N1 associated acute respiratory distress syndrome: a multicenter retrospective cohort study / Fanelli, Vito; Giani, Marco; Grasselli, Giacomo; Mojoli, Francesco; Martucci, Gennaro; Grazioli, Lorenzo; Alessandri, Francesco; Mongodi, Silvia; Sales, Gabriele; Montrucchio, Giorgia; Pizzi, Costanza; Richiardi, Lorenzo; Lorini, Luca; Arcadipane, Antonio; Pesenti, Antonio; Foti, Giuseppe; Patroniti, Nicolò; Brazzi, Luca; Ranieri, VITO MARCO. - In: CRITICAL CARE. - ISSN 1364-8535. - 26:(2022). [10.1186/s13054-022-03906-4]
Extracorporeal membrane oxygenation for COVID-19 and influenza H1N1 associated acute respiratory distress syndrome: a multicenter retrospective cohort study
Francesco Alessandri;Antonio Pesenti;Giuseppe Foti;Marco Ranieri
2022
Abstract
Background: Extracorporeal membrane oxygenation (ECMO) has become an established rescue therapy for severe acute respiratory distress syndrome (ARDS) in several etiologies including influenza A H1N1 pneumonia. The benefit of receiving ECMO in coronavirus disease 2019 (COVID-19) is still uncertain. The aim of this analysis was to compare the outcome of patients who received veno-venous ECMO for COVID-19 and Influenza A H1N1 associated ARDS. Methods: This was a multicenter retrospective cohort study including adults with ARDS, receiving ECMO for COVID- 19 and influenza A H1N1 pneumonia between 2009 and 2021 in seven Italian ICU. The primary outcome was any- cause mortality at 60 days after ECMO initiation. We used a multivariable Cox model to estimate the difference in mor- tality accounting for patients’ characteristics and treatment factors before ECMO was started. Secondary outcomes were mortality at 90 days, ICU and hospital length of stay and ECMO associated complications. Results: Data from 308 patients with COVID-19 (N = 146) and H1N1 (N = 162) associated ARDS who had received ECMO support were included. The estimated cumulative mortality at 60 days after initiating ECMO was higher in COVID-19 (46%) than H1N1 (27%) patients (hazard ratio 1.76, 95% CI 1.17–2.46). When adjusting for confounders, specifically age and hospital length of stay before ECMO support, the hazard ratio decreased to 1.39, 95% CI 0.78–2.47. ICU and hospital length of stay, duration of ECMO and invasive mechanical ventilation and ECMO-associated hemor- rhagic complications were higher in COVID-19 than H1N1 patients. Conclusion: In patients with ARDS who received ECMO, the observed unadjusted 60-day mortality was higher in cases of COVID-19 than H1N1 pneumonia. This difference in mortality was not significant after multivariable adjust- ment; older age and longer hospital length of stay before ECMO emerged as important covariates that could explain the observed difference.File | Dimensione | Formato | |
---|---|---|---|
Fanelli_Extracorporeal-membrane-oxygenation_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
936.99 kB
Formato
Adobe PDF
|
936.99 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.